Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06602648 | MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)(Mol-Mel) | recruiting | — | 100 | University of FlorenceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 |
| Aug 28, 2024 |
| clinicaltrials |
| NCT04853602 | IFx-Hu2.0 Expanded Access Program | available | — | — | TuHURA Biosciences, Inc.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT05079113 | Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting | completed | — | 73 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | recruiting | Phase 2 | 28 | University of LouisvilleOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | terminated | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06299878 | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns](CRISTINA) | unknown | — | 72 | Russian Academy of Medical SciencesOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06246903 | INTER-PATHOLOGIST READER STUDY | unknown | — | 500 | Orlucent, IncINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05446155 | BioMEL- Diagnostic and Prognostic Factors in Melanoma.(BioMEL) | recruiting | — | 2,000 | Region SkaneOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT01942603 | Minimal SN Tumor Burden(Minitub) | active not recruiting | — | 296 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Nov 28, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05253872 | The MELAcare Study: A New Method for Surveillance of Melanoma Patients | recruiting | N/A | 378 | Herlev and Gentofte HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT03843593 | A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery | completed | — | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04551352 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | completed | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 6 | Oct 3, 2022 | clinicaltrials |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | completed | Early Phase 1 | 7 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02857374 | Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy | completed | N/A | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04353050 | Atypical MOLes and Melanoma Early Detection Study (MoleMed)(MoleMed) | unknown | N/A | 350 | Russian Academy of Medical SciencesOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05402046 | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms(CAMELLIA) | unknown | N/A | 605 | MelanomaPRO, RussiaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | terminated | Phase 3 | 20 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 5 | Jan 19, 2022 | clinicaltrials |
| NCT01511913 | A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma(IMAGE) | completed | — | 1,411 | Bristol-Myers SquibbINDUSTRY | 15 | Dec 28, 2021 | clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results(INTEGRATE) | terminated | — | 301 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes(EXPAND) | terminated | — | 72 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT03663647 | Advanced Melanoma in Russian Experience(ADMIRE) | completed | — | 382 | MelanomaPRO, RussiaOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | recruiting | Phase 2 | 40 | Di WuOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03112668 | Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners | completed | N/A | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04789421 | Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management(NET-DAM) | completed | N/A | 3,248 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT04625491 | Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | unknown | — | 300 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Feb 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials